Vascular RhoJ is an effective and selective target for tumor angiogenesis and vascular disruption

Cancer Cell

Volumn 25, Issue 1, 2014, Pages 102-117

  Kim, Chan ^a   Yang, Hanseul ^a   Fukushima, Yoko ^b   Saw, PheiEr ^a   Lee, Junyeop ^a   Park, Jin Sung ^a   Park, Intae ^a   Jung, Jinmyung ^a   Kataoka, Hiroshi ^c   Lee, Doheon ^a   DoHeo, Won ^a   Kim, Injune ^a   Jon, Sangyong ^a   Adams, Ralf H ^d   Nishikawa, Shin Ichi ^c   Uemura, Akiyoshi ^b   Koh, GouYoung ^a  

^a Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c RIKEN Center for Biosystems Dynamics Research   (Japan)

^d MAX PLANCK INSTITUTE FOR MOLECULAR BIOMEDICINE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; CISPLATIN; COMBRETASTATIN A4 PHOSPHATE; GUANINE NUCLEOTIDE BINDING PROTEIN; PROTEIN RHOJ; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SMALL INTERFERING RNA; TAMOXIFEN; UNCLASSIFIED DRUG; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CELL MOTILITY; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; LYMPH VESSEL METASTASIS; MALE; METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR GROWTH; TUMOR VOLUME; WOUND HEALING;

ANGIOGENESIS INHIBITORS; ANIMALS; GENE KNOCKDOWN TECHNIQUES; GTP PHOSPHOHYDROLASES; HUMANS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; RHO GTP-BINDING PROTEINS; RHO-ASSOCIATED KINASES; RHOA GTP-BINDING PROTEIN; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 84892414410     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2013.12.010     Document Type: Article

References (43)

1. Baguley B.C., McKeage M.J. Anticancer potential of tumor vascular disrupting agents: review of the latest clinical evidence. Clin. Investig. 2012, 2:985-993.
2. Beckers C.M.L., van Hinsbergh V.W.M., van Nieuw Amerongen G.P. Driving Rho GTPase activity in endothelial cells regulates barrier integrity. Thromb. Haemost. 2010, 103:40-55.
3. Bergers G., Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 2008, 8:592-603.
4. Bono F., De Smet F., Herbert C., De Bock K., Georgiadou M., Fons P., Tjwa M., Alcouffe C., Ny A., Bianciotto M., et al. Inhibition of tumor angiogenesis and growth by a small-molecule multi-FGF receptor blocker with allosteric properties. Cancer Cell 2013, 23:477-488.
5. Bryan B.A., D'Amore P.A. What tangled webs they weave: Rho-GTPase control of angiogenesis. Cell. Mol. Life Sci. 2007, 64:2053-2065.
6. Carmeliet P., Jain R.K. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011, 473:298-307.
7. Casanovas O., Hicklin D.J., Bergers G., Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005, 8:299-309.
8. Chen H.X., Cleck J.N. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol. 2009, 6:465-477.
9. Chung A.S., Lee J., Ferrara N. Targeting the tumour vasculature: insights from physiological angiogenesis. Nat. Rev. Cancer 2010, 10:505-514.
10. Ebos J.M., Kerbel R.S. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol. 2011, 8:210-221.
11. Ellis L.M., Hicklin D.J. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat. Rev. Cancer 2008, 8:579-591.
12. Ferrara N., Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat. Med. 1999, 5:1359-1364.
13. Ferrara N., Kerbel R.S. Angiogenesis as a therapeutic target. Nature 2005, 438:967-974.
14. Fukumura D., Jain R.K. Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. Microvasc. Res. 2007, 74:72-84.
15. Fukushima Y., Okada M., Kataoka H., Hirashima M., Yoshida Y., Mann F., Gomi F., Nishida K., Nishikawa S.I., Uemura A. Sema3E-PlexinD1 signaling selectively suppresses disoriented angiogenesis in ischemic retinopathy in mice. J.Clin. Invest. 2011, 121:1974-1985.
16. Gerald D., Chintharlapalli S., Augustin H.G., Benjamin L.E. Angiopoietin-2: an attractive target for improved antiangiogenic tumor therapy. Cancer Res. 2013, 73:1649-1657.
17. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86:353-364.
18. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
19. Horsman M.R., Siemann D.W. Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Res. 2006, 66:11520-11539.
20. Joo H.J., Choi D.-K., Lim J.S., Park J.-S., Lee S.-H., Song S., Shin J.H., Lim D.-S., Kim I., Hwang K.-C., Koh G.Y. ROCK suppression promotes differentiation and expansion of endothelial cells from embryonic stem cell-derived Flk1(+) mesodermal precursor cells. Blood 2012, 120:2733-2744.
21. Kamba T., McDonald D.M. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br. J. Cancer 2007, 96:1788-1795.
22. Kaur S., Leszczynska K., Abraham S., Scarcia M., Hiltbrunner S., Marshall C.J., Mavria G., Bicknell R., Heath V.L. RhoJ/TCL regulates endothelial motility and tube formation and modulates actomyosin contractility and focal adhesion numbers. Arterioscler. Thromb. Vasc. Biol. 2011, 31:657-664.
23. Kim S., Kim D., Jung H.H., Lee I.H., Kim J.I.L., Suh J.Y., Jon S. Biol-inspired design and potential biomedical applications of a novel class of high-affinity peptides. Angew. Chem. Int. Ed. 2012, 51:1890-1894.
24. Koh Y.J., Kim H.-Z., Hwang S.-I., Lee J.E., Oh N., Jung K., Kim M., Kim K.E., Kim H., Lim N.-K., et al. Double antiangiogenic protein, DAAP, targeting VEGF-A and angiopoietins in tumor angiogenesis, metastasis, and vascular leakage. Cancer Cell 2010, 18:171-184.
25. Leszczynska K., Kaur S., Wilson E., Bicknell R., Heath V.L. The role of RhoJ in endothelial cell biology and angiogenesis. Biochem. Soc. Trans. 2011, 39:1606-1611.
26. Mancuso M.R., Davis R., Norberg S.M., O'Brien S., Sennino B., Nakahara T., Yao V.J., Inai T., Brooks P., Freimark B., et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J.Clin. Invest. 2006, 116:2610-2621.
27. Masiero M., Simões F.C., Han H.D., Snell C., Peterkin T., Bridges E., Mangala L.S., Wu S.Y., Pradeep S., Li D., et al. A core human primary tumor angiogenesis signature identifies the endothelial orphan receptor ELTD1 as a key regulator of angiogenesis. Cancer Cell 2013, 24:229-241.
28. McDonald D.M., Baluk P. Significance of blood vessel leakiness in cancer. Cancer Res. 2002, 62:5381-5385.
29. Menrad A., Menssen H.D. ED-B fibronectin as a target for antibody-based cancer treatments. Expert Opin. Ther. Targets 2005, 9:491-500.
30. Sawada J., Urakami T., Li F., Urakami A., Zhu W., Fukuda M., Li D.Y., Ruoslahti E., Komatsu M. Small GTPase R-Ras regulates integrity and functionality of tumor blood vessels. Cancer Cell 2012, 22:235-249.
31. Schiller M.R. Coupling receptor tyrosine kinases to Rho GTPases-GEFs what's the link. Cell. Signal. 2006, 18:1834-1843.
32. Sennino B., McDonald D.M. Controlling escape from angiogenesis inhibitors. Nat. Rev. Cancer 2012, 12:699-709.
33. Shojaei F., Wu X., Malik A.K., Zhong C., Baldwin M.E., Schanz S., Fuh G., Gerber H.-P., Ferrara N. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat. Biotechnol. 2007, 25:911-920.
34. Siemann D.W. The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by tumor-vascular disrupting Agents. Cancer Treat. Rev. 2011, 37:63-74.
35. Sun H., Breslin J.W., Zhu J., Yuan S.Y., Wu M.H. Rho and ROCK signaling in VEGF-induced microvascular endothelial hyperpermeability. Microcirculation 2006, 13:237-247.
36. Takase H., Matsumoto K., Yamadera R., Kubota Y., Otsu A., Suzuki R., Ishitobi H., Mochizuki H., Kojima T., Takano S., et al. Genome-wide identification of endothelial cell-enriched genes in the mouse embryo. Blood 2012, 120:914-923.
37. Tozer G.M., Kanthou C., Baguley B.C. Disrupting tumour blood vessels. Nat. Rev. Cancer 2005, 5:423-435.
38. Trédan O., Galmarini C.M., Patel K., Tannock I.F. Drug resistance and the solid tumor microenvironment. J.Natl. Cancer Inst. 2007, 99:1441-1454.
39. Tvorogov D., Anisimov A., Zheng W., Leppänen V.-M., Tammela T., Laurinavicius S., Holnthoner W., Heloterä H., Holopainen T., Jeltsch M., et al. Effective suppression of vascular network formation by combination of antibodies blocking VEGFR ligand binding and receptor dimerization. Cancer Cell 2010, 18:630-640.
40. van der Meel R., Symons M.H., Kudernatsch R., Kok R.J., Schiffelers R.M., Storm G., Gallagher W.M., Byrne A.T. The VEGF/Rho GTPase signalling pathway: a promising target for anti-angiogenic/anti-invasion therapy. Drug Discov. Today 2011, 16:219-228.
41. Wachsberger P., Burd R., Dicker A.P. Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. Clin. Cancer Res. 2003, 9:1957-1971.
42. Wang Y., Nakayama M., Pitulescu M.E., Schmidt T.S., Bochenek M.L., Sakakibara A., Adams S., Davy A., Deutsch U., Lüthi U., et al. Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis. Nature 2010, 465:483-486.
43. Yuan L., Sacharidou A., Stratman A.N., Le Bras A., Zwiers P.J., Spokes K., Bhasin M., Shih S.C., Nagy J.A., Molema G., et al. RhoJ is an endothelial cell-restricted Rho GTPase that mediates vascular morphogenesis and is regulated by the transcription factor ERG. Blood 2011, 118:1145-1153.